Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13324201 | 1.00 | DGAT1 (0.46) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL30511197 | 0.83 | TDP1 (0.37) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL20963156 | 0.80 | MEN1 (0.47) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL24191656 | 0.79 | DGAT1 (0.41) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL191649 | 0.79 | CA12 (0.41) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL1927273 | 0.78 | DGAT1 (0.41) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL29422137 | 0.77 | CA12 (0.41) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL28026126 | 0.77 | CA12 (0.41) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL14182678 | 0.77 | MEN1 (0.41) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL3685404 | 0.77 | MAOA (0.46) | DGAT1CA12CA14CA2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112313209-B | Herbicidal compounds | 先正达农作物保护股份公司 | 2024-07-26 | — | — | CN | disclosed |
| US-12024499-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| WO-2024068518-A1 | 3-HETEROARYL-5-CHLORODIFLUOROMETHYL-1,2,4-OXADIAZOLE AS FUNGICIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-04 | — | — | WO | disclosed |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
| US-11851411-B2 | Herbicidal compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2023-12-26 | — | — | US | disclosed |
| US-11667628-B2 | Compounds for imaging tau proteins that accumulate in brain | NATIONAL INSTITUTES FOR QUANTUM AND RADIOLOGICAL SCIENCE AND TECHNOLOGY (JP) | 2023-06-06 | — | — | US | disclosed |
| US-20230002354-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| US-11542225-B2 | Lipids for use in lipid nanoparticle formulations | Acuitas Therapeutics, Inc. (CA) | 2023-01-03 | — | — | US | disclosed |
| WO-2022112140-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| US-11319408-B2 | Hydrophilic polymer derivative having self-immolative acetal linker and conjugate using same | NOF CORPORATION (JP) | 2022-05-03 | — | — | US | disclosed |
| US-8247534-B2 | Synthesis of radiofluorinated peptide using microwave activation technology | GE HEALTHCARE AS (NO) | 2012-08-21 | — | — | US | disclosed |
| US-8106212-B2 | Substituted enaminocarbonyl compounds | BAYER CROPSCIENCE AG (DE) | 2012-01-31 | — | — | US | disclosed |
| CN-101932565-A | Hydroxylated pyrimidyl cyclopentane as the AKT kinases inhibitor | GENENTECH INC | 2010-12-29 | — | — | CN | disclosed |
| US-20100041719-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100016551-A1 | SYNTHESIS OF RADIOFLUORINATED PEPTIDE USING MICROWAVE ACTIVATION TECHNOLOGY | GE HEALTHCARE AS (NO) | 2010-01-21 | — | — | US | disclosed |
| US-20090247551-A1 | SUBSTITUTED ENAMINOCARBONYL COMPOUNDS | BAYER CROPSCIENCE AG (DE) | 2009-10-01 | — | — | US | disclosed |
| CN-1046724-C | Pyrazolopyridine compounds, pharmaceutical compositions containing them, processes for their preparation and their use | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-11-24 | — | — | CN | disclosed |
| WO-1999041216-A1 | SUPPORTS FOR SOLID STATE CHEMICAL REACTIONS AND METHOD OF USE THEREOF | CHEMBRIDGE CORPORATION (US) | 1999-08-19 | — | — | WO | disclosed |
| CN-1139928-A | Novel compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-01-08 | — | — | CN | disclosed |
| CN-1043717-A | Cephalosporin compound | TANABE SEIYAKU CO (JP) | 1990-07-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247551-A1 | SUBSTITUTED ENAMINOCARBONYL COMPOUNDS | DDT, NPEPPS, L3MBTL4 | DGAT1 1774/4885CA12 4480/4885CA14 4264/4885 |
| US-11851411-B2 | Herbicidal compounds | DDT, CBR3, GLRX3 | DGAT1 762/4885CA12 2531/4885CA14 3039/4885 |
| US-11667628-B2 | Compounds for imaging tau proteins that accumulate in brain | MAPT, FABP7, HTT | DGAT1 3065/4885CA12 3479/4885CA14 3823/4885 |
| US-20230002354-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | DGAT1 3517/4885CA12 2640/4885CA14 3013/4885 |
| US-20100041719-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIF18B | DGAT1 3359/4885CA12 3550/4885CA14 3612/4885 |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | DGAT1 1998/4885CA12 2699/4885CA14 1642/4885 |
| US-20100016551-A1 | SYNTHESIS OF RADIOFLUORINATED PEPTIDE USING MICROWAVE ACTIVATION TECHNOLOGY | VIP, QRFPR, GRPR | DGAT1 2426/4885CA12 2624/4885CA14 1868/4885 |
| US-12024499-B2 | Muscarinic agonists | CHRM1, CHRM2, CHRM3 | DGAT1 3517/4885CA12 2640/4885CA14 3013/4885 |
| US-11542225-B2 | Lipids for use in lipid nanoparticle formulations | LIPC, LIPA, PHOSPHO1 | DGAT1 95/4885CA12 2457/4885CA14 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.